Arie S. Belldegrun's Insider Trades & SAST Disclosures
Arie S. Belldegrun's most recent trade in Allogene Therapeutics Inc was a trade of 1,307,927 Stock Option (Right to buy) done . Disclosure was reported to the exchange on Jan. 24, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Arie S. Belldegrun.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 1,307,927 | 1,307,927 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 369,957 | 2,236,816 (1%) | 0% | 0 | Common Stock | |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 10,000 | 10,000 | - | - | Stock Option (right ot buy) | |
| Kronos Bio Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Ginkgo Bioworks Holdings I... | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 571,428 | 571,428 | - | - | Stock Option | |
| Ginkgo Bioworks Holdings I... | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 432,900 | 432,900 | - | - | Restricted Stock Units | |
| Ginkgo Bioworks Holdings I... | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 105,263 | 194,925 | - | - | Class A Common Stock | |
| Ginkgo Bioworks Holdings I... | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 105,263 | 0 | - | - | Restricted Stock Units | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Purchase of securities on an exchange or from another person at price $ 2.90 per share. | 16 May 2024 | 1,724,137 | 1,724,137 (1%) | 1% | 2.9 | 4,999,997 | Common Stock |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 2.90 per share. | 16 May 2024 | 344,828 | 539,867 (0%) | 0% | 2.9 | 1,000,001 | Common Stock |
| Allogene Therapeutics Inc | Belldegrun S. Arie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 749,398 | 749,398 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | Belldegrun Arie S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 211,973 | 1,866,859 (1%) | 0% | 0 | Common Stock | |
| Kronos Bio Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Ginkgo Bioworks Holdings I... | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 139,860 | 139,860 | - | - | Stock Option | |
| Ginkgo Bioworks Holdings I... | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 105,263 | 105,263 | - | - | Restricted Stock Units | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 1,282,976 | 1,654,886 (1%) | 1% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 994,800 | 994,800 | - | - | Stock Option (Right to Buy) | |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 14 Sep 2022 | 160,000 | 408,693 (1%) | 0% | 5 | 800,000 | Ordinary Shares |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2022 | 160,000 | 0 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2022 | 3,241 | 0 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 31 Aug 2022 | 3,241 | 248,693 (1%) | 0% | 5 | 16,205 | Ordinary Shares |
| Kronos Bio Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Ginkgo Bioworks Holdings I... | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 108,516 | 108,516 | - | - | Stock Option | |
| Ginkgo Bioworks Holdings I... | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 70,921 | 89,662 | - | 0 | Class A Common Stock | |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 1,458,333 | 1,458,333 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Other type of transaction at price $ 0.00 per share. | 14 Mar 2022 | 4,710,120 | 4,710,120 (3%) | 3% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Other type of transaction at price $ 0.00 per share. | 14 Mar 2022 | 4,710,120 | 0 (0%) | 3% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Purchase of securities on an exchange or from another person at price $ 12.60 per share. | 12 Jan 2022 | 155,039 | 195,039 (0%) | 0% | 12.6 | 1,953,491 | Common Stock |
| Kronos Bio Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 20,600 | 20,600 | - | - | Stock Option (Right to Buy) | |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.22 per share. | 24 May 2021 | 379,066 | 583,034 (0%) | 0% | 18.2 | 6,906,583 | Common Stock |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2021 | 379,066 | 0 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2021 | 199,223 | 199,223 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2021 | 53,635 | 203,968 (0%) | 0% | 0 | Common Stock | |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 26 Mar 2021 | 3,241 | 245,452 (1%) | 0% | 5 | 16,205 | Ordinary Shares |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2021 | 3,241 | 0 | - | - | Stock Option (right to buy) | |
| Kronos Bio Inc | Arie S. Belldegrun | Director | 14 Oct 2020 | 1,376,313 | 2,062,063 | - | - | Common Stock | ||
| Kronos Bio Inc | Arie S. Belldegrun | Director | 14 Oct 2020 | 1,304,563 | 0 | - | - | Series A Preferred Stock | ||
| Kronos Bio Inc | Arie S. Belldegrun | Director | 14 Oct 2020 | 685,750 | 685,750 | - | - | Common Stock | ||
| Kronos Bio Inc | Arie S. Belldegrun | Director | 14 Oct 2020 | 650,000 | 0 | - | - | Series Seed Preferred Stock | ||
| Kronos Bio Inc | Arie S. Belldegrun | Director | 14 Oct 2020 | 253,251 | 2,315,314 | - | 16.2 | 4,090,004 | Common Stock | |
| Kronos Bio Inc | Arie S. Belldegrun | Director | 14 Oct 2020 | 240,872 | 679,575 | - | - | Common Stock | ||
| Kronos Bio Inc | Arie S. Belldegrun | Director | 14 Oct 2020 | 228,315 | 0 | - | - | Series A Preferred Stock | ||
| Kronos Bio Inc | Arie S. Belldegrun | Director | 14 Oct 2020 | 182,866 | 438,703 | - | - | Common Stock | ||
| Kronos Bio Inc | Arie S. Belldegrun | Director | 14 Oct 2020 | 173,333 | 0 | - | - | Series Seed Preferred Stock | ||
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Purchase of securities on an exchange or from another person at price $ 47.00 per share. | 04 Jun 2020 | 106,382 | 1,798,163 (1%) | 0% | 47 | 4,999,954 | Common Stock |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Purchase of securities on an exchange or from another person at price $ 47.00 per share. | 04 Jun 2020 | 40,000 | 40,000 (0%) | 0% | 47 | 1,880,000 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges